Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904481 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL11435078 | 0.86 | L3MBTL1 (0.57) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL8876625 | 0.86 | MAOA (0.53) | KDM4EALDH1A1MAOAMAOBCYP3A4 | |
| SCHEMBL29874549 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL3363862 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL4374097 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL410269 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL1115777 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL30428272 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL1001446 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1MAPK1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309315-B2 | Therapy with CD4 binding peptides and radiation | GENMAB A/S (DK) | 2016-04-12 | — | — | US | claimed |
| EP-1951303-B1 | THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION | GENMAB AS (DK) | 2011-02-02 | — | — | EP | claimed |
| US-20100015134-A1 | Therapy With CD4 Binding Peptides and Radiation | GENMAB A/S | 2010-01-21 | — | — | US | claimed |
| EP-1951303-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | Genmab A/S (DK) | 2008-08-06 | — | — | EP | claimed |
| WO-2007019865-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | GENMAB A/S (DK) | 2007-02-22 | — | — | WO | claimed |
| US-20060252674-A1 | Methods for pretreating a subject with extracorporeal photopheresis | THERAKOS, INC. | 2006-11-09 | — | — | US | claimed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | claimed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | claimed |
| US-20040191806-A1 | Assays using crosslinkable immobilized nucleic acids | HUAN BINGFANG (US) | 2004-09-30 | — | — | US | claimed |
| US-6696246-B1 | ALLOWING STRINGENT WASH CONDITIONS REDUCING BACKGROUND SIGNALS WITHOUT LOSS OF HYBRIDS | NAXCOR, INC. | 2004-02-24 | — | — | US | claimed |
| US-4791062-A | FELINE VIRAL RHINOTRACHEITIS; FUROCOUMARIN INACTIVATED FELINE HERPES VIRUS I | DIAMOND SCIENTIFIC CO. (US) | 1988-12-13 | — | — | US | claimed |
| US-4748120-A | Photochemical decontamination treatment of whole blood or blood components | DIAMOND SCIENTIFIC CO. (US) | 1988-05-31 | — | — | US | claimed |
| US-4727027-A | FUROCOUMARIN DERIVATIVE AND ULTRAVIOLET IRRADIATION | DIAMOND SCIENTIFIC CO. (US) | 1988-02-23 | — | — | US | claimed |
| US-4599303-A | PSORALEN DERIVATIVES | HRI ASSOCIATES, INC. (US) | 1986-07-08 | — | — | US | claimed |
| EP-0165313-A4 | NUCLEIC ACID HYBRIDIZATION ASSAY. | HRI RES INC (US) | 1986-05-16 | — | — | EP | claimed |
| EP-0165313-A1 | NUCLEIC ACID HYBRIDIZATION ASSAY. | HYDROCARBON RESEARCH INC (US) | 1985-12-27 | — | — | EP | claimed |
| WO-1985002628-A1 | NUCLEIC ACID HYBRIDIZATION ASSAY | HRI RESEARCH, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| EP-0124363-A2 | Photochemical decontamination treatment of whole blood or blood components | DIAMOND SCIENTIFIC CO. (US) | 1984-11-07 | — | — | EP | claimed |
| US-4196281-A | CROSSLINKING DNA AND RNA TO INTERFERE WITH REPRODUCTION | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1980-04-01 | — | — | US | claimed |
| US-4124598-A | INHIBITORS OF RNA REPLICATION, INACTIVATION OF VIRUSES, PHOTOCHEMO | HOFFMANN-LA ROCHE INC. (US) | 1978-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134031-A1 | Phototherapy compositions and methods | VCL, TYR, TTPA | KDM4E 4478/4885ALDH1A1 1344/4885MAPK1 3586/4885 |
| US-20100015134-A1 | Therapy With CD4 Binding Peptides and Radiation | CD4, CD74, SELPLG | KDM4E 4522/4885ALDH1A1 4414/4885MAPK1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.